Advertisements



Bristol-Myers can be "a sweet pill" for investors, Barron"s says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 12th, 2019

Why Bristol-Myers Squibb Can Be a Sweet Pill for Investors

Wall Street has soured on the deal for Celgene, but Bristol-Myers has one of the lowest valuations in the drug sector and could itself become a takeover target.....»»

Category: topSource: barronsJan 13th, 2019

Is Bristol-Myers (BMY) a Solid Pick for Value Investors?

Let's see if Bristol-Myers (BMY) stock is a good choice for value-oriented investors right now from multiple angles. Want the latest recommendations from Zacks Inve.....»»

Category: dealsSource: nytMar 11th, 2019

Here"s What Starboard Might Be Planning for Papa John"s and Bristol-Myers

The hedge fund has a history in both restaurants and in health care. It isn’t clear what Starboard CEO Jeff Smith plans this time, but investors should take note......»»

Category: topSource: barronsFeb 5th, 2019

Barron"s Picks And Pans: Amazon, Apple, Bristol-Myers, Starbucks And More

This weekend's Barron's cover story reveals the results of the Barron's 2019 Investment Roundtable. Other featured articles examine safe dividend growth stocks and the best stock funds for risky markets. read more.....»»

Category: blogSource: benzingaJan 13th, 2019

Should Investors Like Bristol-Myers" Buyout of Celgene?

The pharmaceutical giant’s $74 billion bid for the biotechnology player sent the acquirer’s shares significantly lower, but that’s hardly unusual......»»

Category: topSource: foxnewsJan 7th, 2019

Celgene Investors Should Take the Money and Run

With Celgene stock trading 25% higher after Bristol-Myers Squibb made a $74 billion acquisition offer, Celgene investors probably shouldn’t wait around to see if the deal closes......»»

Category: topSource: barronsJan 4th, 2019

Celgene shareholders should sell now, Leerink says

Bristol-Myers Squibb Co.'s agreement to acquire Celgene Corp. is "an exit opportunity for Celgene shareholders," Leerink analysts wrote in a note to investors Thur.....»»

Category: topSource: marketwatchJan 3rd, 2019

Merck profit beats, but Keytruda sales fail to impress

Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy......»»

Category: topSource: reutersJul 27th, 2018

Merck Cements Lead in Lung Cancer as Bristol-Myers Fizzles

Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung cancer, by far the deadliest form of cancer in the U.S......»»

Category: topSource: moneycentralApr 16th, 2018

Bristol-Myers price target raised to $62 from $59 at BMO Capital

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall3 hr. 43 min. ago

Bristol-Myers Squibb and Starboard Value square off over Celgene deal

L.....»»

Category: topSource: bizjournalsMar 19th, 2019

Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

Zacks.....»»

Category: topSource: redinewsMar 19th, 2019

Starboard files presentation opposing Bristol-Myers" proposed acquistion of Celgene

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 19th, 2019

Bristol-Myers announces filing of presentation on Celgene deal benefits

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 19th, 2019

Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (V.....»»

Category: dealsSource: nytMar 18th, 2019

Barron"s On: Investing As Globalization Declines

This weekend's Barron's cover story discusses what investors should know about the decline of globalization. See how some multinational companies already have been changing the way they operate. read more.....»»

Category: blogSource: benzingaMar 18th, 2019

Bristol-Myers, Pfizer alliance announces results from Phase 4 AUGUSTUS trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 17th, 2019

Barron"s Picks And Pans: Boeing, Hasbro, Kinder Morgan, US Steel And More

This weekend's Barron's cover story discusses what investors should know about the decline of globalization. Other featured articles examine prospects for an embattled aerospace giant and domestic steel makers. read more.....»»

Category: blogSource: benzingaMar 17th, 2019

For Bristol-Myers Squibb"s Sake, Celgene Merger Should Be Voted Down

For Bristol-Myers Squibb"s Sake, Celgene Merger Should Be Voted Down.....»»

Category: topSource: seekingalphaMar 15th, 2019

Bristol-Myers Squibb Company (BMY) Management Presents at Barclays 2019 Global Healthcare Conference Call (Transcript)

Bristol-Myers Squibb Company (BMY) Management Presents at Barclays 2019 Global Healthcare Conference Call (Transcript).....»»

Category: topSource: seekingalphaMar 13th, 2019